Details for Patent: 11,090,294
Which drugs does patent 11,090,294 protect, and when does it expire?
Patent 11,090,294 protects ANORO ELLIPTA and TRELEGY ELLIPTA and is included in two NDAs.
This patent has eighty-four patent family members in forty-three countries.
Summary for Patent: 11,090,294
| Title: | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
| Abstract: | Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided. |
| Inventor(s): | Darrell Baker, Mark Bruce, Glenn Crater, Brian Noga, Marian Thomas, Patrick Wire |
| Assignee: | Glaxo Group Ltd |
| Application Number: | US15/678,246 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 11,090,294
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | ANORO ELLIPTA | umeclidinium bromide; vilanterol trifenatate | POWDER;INHALATION | 203975-001 | Dec 18, 2013 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | ⤷ Start Trial | ||||
| Glaxosmithkline | TRELEGY ELLIPTA | fluticasone furoate; umeclidinium bromide; vilanterol trifenatate | POWDER;INHALATION | 209482-001 | Sep 18, 2017 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) COMPRISING THE ONCE PER DAY ADMINISTRATION OF TRELEGY ELLIPTA, 100 MCG FLUTICASONE FUROATE/62.5 MCG UMECLIDINIUM/25 MCG VILANTEROL | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 11,090,294
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0921075.8 | Dec 1, 2009 |
International Family Members for US Patent 11,090,294
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2506844 | ⤷ Start Trial | 300942 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2506844 | ⤷ Start Trial | PA2018011 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2506844 | ⤷ Start Trial | 122018000060 | Germany | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
